The MEA epirubicin market is expected to grow from US$ 11,319.57 thousand in 2022 to US$ 13,896.58 thousand by 2028; it is estimated to grow at a CAGR of 3.5% from 2022 to 2028.
Increase in Number of Cancer Research Programs to Boost Epirubicin Market Growth
Cancer is the one of the leading causes of mortality across the region. Furthermore, several reasearchers across the region are working on cancer research programs. Some research is fundamental, exploring questions as diverse as the biological foundations of cancer and the social factors that affect cancer risk. Several research efforts have taken place in recent years. For instance, the Breast Specialized Programs of Research Excellence (Breast SPOREs) are designed to move basic scientific findings into clinical settings quickly. The Breast SPOREs support the development of new therapies, technologies, and studies for a better understanding of tumor resistance, diagnosis, prognosis, screening, prevention, and treatment of breast cancer. Secondly, the Cancer Intervention and Surveillance Modeling Network (CISNET) focuses using modeling to improve knowledge to prevent, early detection, screening, and treatment affect breast cancer results. Ongoing programs help prevention and early detection research in different cancers. The factors mentioned above would fuel the growth of the epirubicin market across the region.
Market Overview
The MEA epirubicin market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the MEA. The market growth is attributed to the huge population base, increasing prevalence of cancer, growing research studies, and a surge in healthcare facilities across the region. Saudi Arabia is one of the important countries in the region that has significant scope for cancer treatment. The healthcare system in the country is developing rapidly, and an increasing number of international companies are developing medical and research teams in the country. As per the data of WHO, in 2018, approximately 24,485 new cancer cases were registered in the country; out of which, breast cancer cases were ~3,629 and 3,564 were colorectum cancer cases. Moreover, in 2012, the total number of cancer incident cases reported by the Saudi Cancer Registry was 12,309. In Saudi Arabia, rising healthcare spending and well-established hospital and tertiary care centers fuel the market growth. The government has increased healthcare and social affairs expenditure by 48% to US$ 42.64 billion (SR 160 billion) for the development of new healthcare centers, hospitals, and primary care centers. Thus, such initiatives by the government, penetration of international market players, and increasing prevalence of cancer are expected to drive the growth of the cancer vaccines market in Saudi Arabia.
MEA Epirubicin Market Segmentation
The MEA epirubicin market is segmented based on dosage, application, distribution channel, and country
Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Salius Pharma Pvt Ltd, and Teva Pharmaceutical Industries Ltd. are the leading companies operating in the MEA epirubicin market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 11,319.57 thousand |
| Market Size by 2028 | US$ 13,896.58 thousand |
| CAGR (2022 - 2028) | 3.5% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Dosage
|
| Regions and Countries Covered |
Middle East and Africa
|
| Market leaders and key company profiles |
|
The Middle East & Africa Epirubicin Market is valued at US$ 11,319.57 thousand in 2022, it is projected to reach US$ 13,896.58 thousand by 2028.
As per our report Middle East & Africa Epirubicin Market, the market size is valued at US$ 11,319.57 thousand in 2022, projecting it to reach US$ 13,896.58 thousand by 2028. This translates to a CAGR of approximately 3.5% during the forecast period.
The Middle East & Africa Epirubicin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Epirubicin Market report:
The Middle East & Africa Epirubicin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Epirubicin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Epirubicin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Epirubicin Market
